MHC Class II Presentation of Endogenously Expressed Antigens by Transfected Dendritic Cells
Overview
Authors
Affiliations
Dendritic cells (DC) present immunogenic epitopes of antigens in the context of MHC class I and class II molecules in association with costimulatory molecules, and efficiently activate both cytotoxic T cells and T helper cells. Gene modified DC expressing antigen encoding cDNA represent a particularly attractive approach for the immunotherapy of disease. We previously described a gene delivery system for DC based on receptor-mediated endocytosis of ligand/polyethylenimine (PEI) DNA transfer complexes that target cell surface receptors which are abundantly expressed on DC. Employing this gene delivery system, DC were generated that express chicken ovalbumin (OVA) cDNA as a model antigen and introduce antigen into the MHC class I presentation pathway. We demonstrate here that modification of OVA cDNA as transferrin receptor (TfR) or invariant chain (Ii) fusions effectively generate MHC class II specific immune responses in addition to MHC class I responses. TfR-OVA contains the membrane anchoring region of transferrin receptor and represents a membrane-bound form of OVA for access to the MHC class II compartment. Ii-OVA fusions directly target the MHC class II processing pathway. Thus, modification of antigen encoding cDNA represents a convenient and effective means to direct antigens to MHC class II presentation and thus to generate T cell help.
Immune evasion through mitochondrial transfer in the tumour microenvironment.
Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T Nature. 2025; 638(8049):225-236.
PMID: 39843734 PMC: 11798832. DOI: 10.1038/s41586-024-08439-0.
MHCI trafficking signal-based mRNA vaccines strengthening immune protection against RNA viruses.
Zhang Y, Zhai S, Qin S, Chen Y, Chen K, Huang Z Bioeng Transl Med. 2025; 10(1):e10709.
PMID: 39801759 PMC: 11711215. DOI: 10.1002/btm2.10709.
Tay R, P L, Pang S, Low K, Tay H, Ho C Theranostics. 2024; 14(16):6138-6160.
PMID: 39431019 PMC: 11488102. DOI: 10.7150/thno.95527.
Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector.
Tai J, Nishikawa T, Hayashi H, Kuan Y, Yamashita K, Nakagami H Vaccines (Basel). 2024; 12(7).
PMID: 39066395 PMC: 11281653. DOI: 10.3390/vaccines12070757.
Bacterial delivery of therapeutic proteins to the nuclei of cancer cells.
Bloom S, OHare N, Forbes N Biotechnol Bioeng. 2023; 120(5):1437-1448.
PMID: 36710503 PMC: 10101893. DOI: 10.1002/bit.28340.